2026-04-13T03:06:15Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4706152024-11-04T06:28:25Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Ma, Cheng-Xu author Ma, Xiao-Ni author Guan, Cong-Hui author Li, Ying-Dong author Mauricio Puente, Dídac author Fu, Song-Bo author Universitat Autònoma de Barcelona author 2022 Altres ajuts: Hospital Fund of the First Hospital of Lanzhou University (ldyyyn2020-93); Construction Program of Gansu Provincial Clinical Medical Research Center for Endocrine Diseases (20JR10FA667); Gansu Provincial Natural Science Foundation (20JR10RA681); Science and Technology Development of the Chinese Central Government to Guide Local in 2020 (1004TCYA032). Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM. http://hdl.handle.net/2072/470615 Type 2 diabetes mellitus Cardiovascular diseases Hyperlipidemia Hypertension Therapy principle Antidiabetic therapy Cardiovascular disease in type 2 diabetes mellitus : progress toward personalized management